Anglia Ruskin Clinical Trials Unit (ARCTU) is a research partnership between Anglia Ruskin University, NHS Trusts from Cambridgeshire, Essex and Hertfordshire, and industry partners.
Together, our NHS Trusts cover a local patient population of over 3 million. In addition, our two tertiary centres; The Essex Cardiothoracic Centre and St Andrews Centre for Plastic Surgery and Burns, takes this population to over 10 million.
Our aim is to work with hospital trusts, healthcare providers, commissioners and commercial companies to increase opportunities for patients to take part in both investigator led and commercial trials.
For our investigator led trials we aim to support investigators through each step of the clinical trial lifecycle. We offer investigators the support to take their study from a basic idea and develop it into a well-designed study. An investigator can be anyone working in a clinical environment (e.g. doctors, nurses and allied health professionals).
We also work with SMEs (small to medium-sized enterprises) and larger commercial companies who are looking to test their products in a clinical environment. The support we offer ranges from providing advice on the regulatory environment in the UK, to helping to plan and run large-scale studies.
Timing of High-Dose Rate Brachytherapy With External Beam Radiotherapy in intermediate and High-Risk Localized Prostate CAncer (THEPCA) Patients and its Effects on Toxicity and Quality of Life: Protocol of a Randomized Feasibility Trial. Sreekanth Palvai, Michael Harrison, Sharon Shibu Thomas, Karen Hayden, James Green, Oliver Anderson, Lavinia Romero, Richard Lodge, Patricia Burns, Imtiaz Ahmed; JMIR Research Protocols; www.ncbi.nlm.nih.gov/pmc/articles/PMC4430680/.
The feasibility of finger prick autologous blood (FAB) as a novel treatment for severe dry eye disease (DED): protocol for a randomised controlled trial. Shafi Balal, Arit Udoh, Yannis Pappas, Erica Cook, Garry Barton, Ali Hassan, Karen Hayden, Rupert Richard, Alexander Bourne, Sajjad Ahmad, Shahina Pardhan, Michael Harrison, Benjamin Sharma, Mohammad Wasil, Anant Sharma.
Feasibility randomised multicentre, double-blind, double-dummy controlled trial of anakinra, an interleukin-1 receptor antagonist versus intramuscular methylprednisolone for acute gout attacks in patients with chronic kidney disease (ASGARD): protocol study. Gowrie Balasubramaniam, Trisha Parker, David Turner, Mike Parker, Jonathan Scales, Patrick Harnett, Michael Harrison, Khalid Ahmed, Sweta Bhagat, Thiraupathy Marianayagam, Costantino Pitzalis, Christian Mallen, Edward Roddy, Mike Almond, Bhaskar Dasgupta.
Karen Hayden, Director
Jufen Zhang, Trials Statistician
Carmel Moore, Coordinator
Please email: firstname.lastname@example.org
Anglia Ruskin Clinical Trials Unit
Anglia Ruskin University
Bishops Hall Lane
Chelmsford, CM1 1SQ
Tel: 01245 684630